Mirum Pharmaceuticals (MIRM) Cost of Revenue (2021 - 2026)

Mirum Pharmaceuticals' Cost of Revenue history runs 6 years deep, the most recent figure standing at $28.8 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 25.14% year-over-year to $28.8 million in Q1 2026; TTM through Mar 2026 was $106.0 million, a 22.11% increase from a year earlier, with the FY2025 full-year figure at $100.2 million, up 22.78% from the prior year.
• Cost of Revenue grew to $28.8 million in Q1 2026 per MIRM's latest filing, from $28.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $28.8 million in Q1 2026 and bottomed at $2.4 million in Q1 2022.
• The 5-year median for Cost of Revenue is $20.2 million (2024), against an average of $15.9 million.
• Across the five-year window, Cost of Revenue soared 456.74% in 2023 and decreased 8.95% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $4.5 million in 2022, then surged by 456.74% to $25.0 million in 2023, then fell by 8.95% to $22.8 million in 2024, then gained by 24.07% to $28.3 million in 2025, then rose by 1.91% to $28.8 million in 2026.
• Per Business Quant, the three latest MIRM Cost of Revenue figures stand at $28.8 million (Q1 2026), $28.3 million (Q4 2025), and $25.5 million (Q3 2025).